Novo Nordisk Stock Surge on Encouraging Weight Loss Tablet Data
The market value of the Denmark-based pharmaceutical firm jumped by more than £6.5bn following clinical trial results showed that its oral anti-obesity medication produced nearly as much weight reduction as its injectable counterpart.
Stock in the drugmaker gained by over 4.5% on the trading day as investors grew optimistic about its potential to regain its competitive position in the face of increasing rivalry from competing firms and lower-cost generic alternatives of GLP-1 drugs.
The latest clinical trial demonstrated that an oral formulation alternative of Wegovy led to substantial reduction in body weight, with nearly one in three participants shedding 20% or more of their body mass. Reported side effects were similar to those of the injection-based therapy.
This marks the first oral GLP-1 medication submitted to the US Food and Drug Administration for approval, and regulatory clearance is expected by the end of this year. Manufacturing has commenced at the firm’s American sites.
This progress puts Novo Nordisk in direct competition with US rival its industry counterpart, which is also developing a daily weight loss pill known as its oral candidate. Trial findings from Eli Lilly showed that 20% of patients lost at least one-fifth of their mass over a 72-week period.
While injection therapies are enjoying broad acceptance, they are expensive and often facing limited availability. Oral versions are generally easier to produce, keep, and take, and could possibly be sold at a more affordable cost.
Market experts suggest that oral anti-obesity drugs could achieve annual sales as high as ten billion dollars, with some projections pointing to a maximum potential of up to $25 billion.
Shares of companies specializing in weight management drugs have substantially outperformed other pharmaceutical stocks over the past five years, highlighting robust market interest in this expanding sector.
